255 related articles for article (PubMed ID: 34146757)
1. Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors - A nationwide population-based cohort study.
Kim HW; Kim JS; Lee SH
Lung Cancer; 2021 Aug; 158():107-114. PubMed ID: 34146757
[TBL] [Abstract][Full Text] [Related]
2. Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study.
Bae S; Kim YJ; Kim MJ; Kim JH; Yun SC; Jung J; Kim MJ; Chong YP; Kim SH; Choi SH; Kim YS; Lee SO
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34521732
[TBL] [Abstract][Full Text] [Related]
3. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
Icht O; Darzi N; Shimony S; Jacobi O; Reinhorn D; Landman Y; Mutai R; Averbuch I; Shochat T; Spectre G; Raanani P; Rotem O; Dudnik E; Peled N; Zer A; Leader A
J Thromb Haemost; 2021 May; 19(5):1250-1258. PubMed ID: 33605020
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
Khorana AA; Palaia J; Rosenblatt L; Pisupati R; Huang N; Nguyen C; Barron J; Gallagher K; Bond TC
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657815
[TBL] [Abstract][Full Text] [Related]
5. Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non-Small-Cell Lung Cancer and Synchronous Brain Metastases.
Mahashabde R; Bhatti SA; Martin BC; Painter JT; Rodriguez A; Ying J; Li C
JCO Oncol Pract; 2023 Nov; 19(11):1009-1019. PubMed ID: 37729600
[TBL] [Abstract][Full Text] [Related]
6. Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study.
Iwai C; Jo T; Konishi T; Fujita A; Michihata N; Matsui H; Fushimi K; Yasunaga H
Cancer Immunol Immunother; 2023 Nov; 72(11):3581-3591. PubMed ID: 37540262
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre.
Chan GH; Gwee YX; Low JL; Huang Y; Chan ZY; Choo JR; Ngoi NY; LE Ang Y; Muthu V; Chong WQ; Wong A; Soo RA
Lung Cancer; 2020 Aug; 146():145-153. PubMed ID: 32540557
[TBL] [Abstract][Full Text] [Related]
8. Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy.
Chen HW; Kuo YW; Chen CY; Chang CH; Wang SM; Chien YC; Lu WC; Chen JP; Chang CY; Wei YF; Chang SC; Shu CC; Wang JY; Liao WY; Wang HC; Yu CJ
Oncologist; 2024 Apr; 29(4):e498-e506. PubMed ID: 38227604
[TBL] [Abstract][Full Text] [Related]
9. Incidence of safety events after immune checkpoint inhibitor initiation for advanced-stage non-small-cell lung cancer: a real-world study.
Beachler DC; Lamy FX; Kolitsopoulos F; Dinh J; Papazian A; Jamal-Allial A; Mahmoudpour SH; Michelon E; Verpillat P
Future Oncol; 2022 Aug; 18(26):2891-2901. PubMed ID: 35848218
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
11. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors and Tuberculosis Infection in Lung Cancer: A Case Series and Systematic Review With Pooled Analysis.
He Y; Peng D; Liang P; Long J; Liu A; Zeng Z
J Clin Pharmacol; 2023 Apr; 63(4):397-409. PubMed ID: 36309847
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A
ESMO Open; 2021 Oct; 6(5):100252. PubMed ID: 34461483
[TBL] [Abstract][Full Text] [Related]
14. Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer.
Altan M; Soto F; Xu T; Wilson N; Franco-Vega MC; Simbaqueba Clavijo CA; Shannon VR; Faiz SA; Gandhi S; Lin SH; Lopez P; Zhong L; Akhmedzhanov F; Godoy MCB; Shroff GS; Wu J; Khawaja F; Kim ST; Naing A; Heymach JV; Daniel-Macdougall C; Liao Z; Sheshadri A
Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):630-639. PubMed ID: 37507279
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina.
Atchley WT; Alvarez C; Saxena-Beem S; Schwartz TA; Ishizawar RC; Patel KP; Rivera MP
Chest; 2021 Aug; 160(2):731-742. PubMed ID: 33621599
[TBL] [Abstract][Full Text] [Related]
16. Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors.
Baek YH; Kang EJ; Hong S; Park S; Kim JH; Shin JY
Int J Cancer; 2022 Apr; 150(8):1291-1300. PubMed ID: 34877670
[TBL] [Abstract][Full Text] [Related]
17. Clinical and financial impact of immune checkpoint inhibitors following platinum chemotherapy in patients with advanced or metastatic non-small cell lung cancer: a nationwide population-based study.
Ji HW; Chun S; Lee JM; Park SC; Han CH; Kim CY; Lee SC
Transl Lung Cancer Res; 2024 Jan; 13(1):46-59. PubMed ID: 38404998
[TBL] [Abstract][Full Text] [Related]
18. Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study.
Deschênes-Simard X; Richard C; Galland L; Blais F; Desilets A; Malo J; Cvetkovic L; Belkaid W; Elkrief A; Gagné A; Hamel MA; Orain M; Joubert P; Ghiringhelli F; Routy B; Blais N
Thromb Res; 2021 Sep; 205():29-39. PubMed ID: 34246011
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
20. Risk of pneumonitis in non-small cell lung cancer patients with preexisting interstitial lung diseases treated with immune checkpoint inhibitors: a nationwide retrospective cohort study.
Sawa K; Sato I; Takeuchi M; Kawakami K
Cancer Immunol Immunother; 2023 Mar; 72(3):591-598. PubMed ID: 35994088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]